Combining adebrelimab with chemotherapy for lung cancer treatment
Official title: A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer
Run by The First Affiliated Hospital of Guangzhou Medical University · NCT06775275 · Data updated 2026-11-12
This study is testing if adding adebrelimab to chemotherapy helps patients with early-stage lung cancer feel better and have better treatment outcomes before surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University Academic / other |
| Drugs / interventions | chemotherapy, adebrelimab, bevacizumab |
| Locations | 1 site (Guangzhou) |
| Status | Recruiting |
| Started | September 24, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2029 |
| Registry record updated | January 15, 2025 |
| Trial ID | NCT06775275 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with resectable non-squamous non-small cell lung cancer and good pulmonary function.
✕Probably not a fit
Patients with small cell lung cancer, squamous cell carcinoma, or those who have previously received certain immunotherapies or anti-angiogenic drugs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase II clinical trial evaluates the safety and efficacy of adebrelimab in combination with chemotherapy, with or without bevacizumab, for patients with resectable Stage II-IIIB non-small cell lung carcinoma (NSCLC). The study is multicenter and randomized, focusing on treatment-naive patients who have not undergone prior surgery or chemotherapy. Participants will receive neoadjuvant therapy followed by surgical intervention, and the study will also explore biomarkers related to treatment efficacy.
Why it matters
Potential benefit: If successful, this treatment approach could improve outcomes for patients with resectable lung cancer by enhancing the effectiveness of neoadjuvant therapy.
How similar studies have gone: While this approach is being explored in this specific context, similar combinations of immunotherapy and chemotherapy have shown promise in other studies, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Resectable NSQ NSCLC * Age 18-65 years * male or female * ECOG 0-1 * Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer * Subjects must have adequate pulmonary function for the intended pneumonectomy; Exclusion Criteria: * SCLC or SQ NSCLC * previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc. * patients who have previously used anti-angiogenic drugs; * allergic to any component of the study drug or chemotherapy drugs * patients with any severe and or uncontrolled disease
Where it's running
-
Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China Recruiting
Study contacts
- Principal investigator: Jianxing He — The First Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Jianxing He
- Email: jianxing.he@gmail.com
- Phone: +86-20-83062807
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases
This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.
-
Combination treatment for advanced liver cancer
This study is testing a new combination of treatments for people with advanced liver cancer to see if it can help them respond better and live longer.
-
Treatment for advanced liver cancer using new drug combinations
This study is testing whether a new combination of drugs can help people with advanced liver cancer live longer and feel better compared to another treatment option.
-
Combining chemotherapy and immunotherapy for advanced colorectal cancer treatment
This study is testing a new combination of chemotherapy and immunotherapy to see if it helps people with advanced colorectal cancer live longer and feel better.
-
Treatment for advanced liver cancer using TACE with new medications
This study is testing a new treatment combining TACE with two medications to see if it helps people with advanced liver cancer who can't have surgery.
-
Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer
This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.